Coherus Oncology (CHRS) Short-term Investments (2017 - 2026)

Coherus Oncology has disclosed Short-term Investments across 9 years of filings, most recently posting $51.8 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $51.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $51.8 million (changed N/A YoY), and the FY2025 annual result was $83.2 million, changed N/A from the prior year.
• Short-term Investments came in at $51.8 million for Q1 2026 at Coherus Oncology, down from $83.2 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $128.1 million in Q4 2022 to a low of $14.9 million in Q4 2023.
• The 4-year median for Short-term Investments is $71.8 million (2023), against an average of $69.1 million.
• Peak annual rise in Short-term Investments reached 88.41% in 2023, while the deepest fall reached 88.41% in 2023.
• Coherus Oncology's Short-term Investments stood at $128.1 million in 2022, then sank by 88.41% to $14.9 million in 2023, then surged by 460.32% to $83.2 million in 2025, then tumbled by 37.76% to $51.8 million in 2026.
• The last three Short-term Investments figures came in at $51.8 million (Q1 2026), $83.2 million (Q4 2025), and $88.3 million (Q3 2025), per Business Quant data.